Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11527 posts found.

Pfizer to seek US approval for crizotinib next year

November 1, 2010 Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer

Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …
News

German rebates to cost pharma 1 billion euro

November 1, 2010 Sales and Marketing BPI, German pharma market, Germany, Gesetzliche Krankenversicherung, healthcare costs

The pharma industry will contribute over 1 billion euro ($1.4 billion) to Germany’s cost-containment efforts by the end of 2010. …
News

GSK signs rare diseases deal with Amicus

November 1, 2010 Research and Development, Sales and Marketing Amicus Therapeutics, Fabrazyme, Fabry disease, GSK, GlaxoSmithKline, pharmacological chaperones

GlaxoSmithKline is partnering with US biopharmaceutical company Amicus Therapeutics to develop and commercialise its late-stage Fabry disease drug Amigal. GSK …
News

Cross-functional marketing leadership

November 1, 2010 Sales and Marketing Nikki Atkins, WG Consulting Healthcare, leadership, marketing strategies, pharma marketing

Building a multi-disciplinary team across a pharma company is a tough challenge – but the demands of the modern development …
Feature

Patent expiries bite into AstraZeneca revenues

October 29, 2010 Sales and Marketing AstraZeneca, Crestor, Q3, Seroquel

Generic competition and a major drop off in pandemic influenza products saw AstraZeneca’s revenue fall for the third quarter. Revenue …
News

MabThera gains maintenance therapy licence

October 29, 2010 Medical Communications, Sales and Marketing MabThera, Rituxan, Roche, lymphoma

Roche’s MabThera has been approved as a maintenance therapy for follicular lymphoma, a common type of blood cancer. Maintenance treatment …
News

Watson submits Crestor copycat

October 28, 2010 Sales and Marketing AstraZeneca, Crestor, Watson, generic, patent

 Watson Pharmaceuticals is seeking to launch a generic version of  AstraZeneca cholesterol blockbuster Crestor, exploiting weaknesses in its patent. The …
News

Rep’s shotgun request misfires

October 28, 2010 Sales and Marketing ABPI Code of Practice, PMCPCA, Sanofi-Aventis

Sanofi-Aventis has been found in breach of the ABPI Code over the conduct of one of its representatives in relation …
News

NICE refuses cancer drugs Arzerra, Torisel and Levact

October 27, 2010 Sales and Marketing Arzerra, GSK, NICE, Napp Pharmaceuticals, Pfizer, Torisel, Treanda, cancer drugs

NICE has refused to recommend a trio of cancer drugs for NHS use – but in two cases says this …
News

£600m confirmed for three year Cancer Drugs Fund

October 27, 2010 Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NICE, cancer drugs, value-based pricing

The NHS will get the extra money it was promised to improve patient access to cancer medicines not backed by …
News

Pharma engages HTA bodies in early-stage drug discussions

October 27, 2010 Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, EMA, European Medicines Agency, GlaxoSmithKline, Johnson & Johnson, health technology assessment, hta

Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA). AstraZeneca, …
News

Minister confirms NICE will be sidelined in drug evaluation

October 26, 2010 Sales and Marketing Andrew Lansley, Lord Howe, NICE, PPRS, medicines pricing, value-based pricing

A health minister has confirmed NICE will be “moved” from its current central role in health technology assessment to make …
News

Sowing into Good Ground: Using “personalized medicine” for optimal treatment value

October 26, 2010 Sales and Marketing Kinapse, White paper

As demonstrating value for the “average patient” becomes ever more difficult, Health Economics and Outcomes Research leaders can use “personalised …
Feature
White paper

Novartis’ Lucentis recommended for wider EU licence

October 25, 2010 Sales and Marketing CHMP, Genentech, Lucentis, Novartis, diabetic macular edema, ranibizumab

Novartis’ Lucentis has been recommended for approval in Europe to treat people suffering from vison loss due to diabetes. The …
News

Arena’s obesity treatment lorcaserin rejected by FDA

October 25, 2010 Sales and Marketing Arena Pharma, Eisai, FDA, FDA complete response letter, lorcaserin, obesity

A new weight loss drug has been rejected by the FDA because of numerous concerns about side-effects and limited efficacy. …
News
The Gateway to Local Adoption Series

Latest content

Scots neonatal innovations target hearing loss and earlier care

August 28, 2026

FDA grants De Novo authorisation to light-filtering device for migraine

August 28, 2026

Southgate opens Innovation Lab for logistics and fulfilment development

August 27, 2026

Bioptimus partners with Cancer Research Horizons to expand AI cancer data set

August 27, 2026

Agentis Health Group acquires Clinical Pharmacist Solutions

August 26, 2026